Iván J. Núñez-Gil

Dr. Iván J. Núñez-Gil

Cardiology, Hospital Clínico San Carlos, Madrid, Spain
orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2018 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
AKAkram Kawsara
Akram Kawsara
INIván J. Núñez-Gil
Iván J. Núñez-Gil
FAFahad Alqahtani
Fahad Alqahtani
JMJason Moreland
Jason Moreland
CRCharanjit S. Rihal
Charanjit S. Rihal
MAMohamad Alkhouli
Mohamad Alkhouli

1 January 2021 in The Lancet
Verified
Journal Article
Closed access
Fabrizio D'AscenzoFabrizio D'Ascenzo
Fabrizio D'Ascenzo
OFOvidio De Filippo
Ovidio De Filippo
GGGuglielmo Gallone
Guglielmo Gallone
GMGianluca Mittone
Gianluca Mittone
MDMarco A. Deriu
Marco A. Deriu
YAYasir Arfat
Yasir Arfat

27 April 2011 in Heart
Verified
Journal Article
Open access
PDF file
ASAida Suárez-Barrientos
Aida Suárez-Barrientos
PLPedro López-Romero
Pedro López-Romero
DVDavid Vivas
David Vivas
FCFrancisco Castro-Ferreira
Francisco Castro-Ferreira
INIván J. Núñez-Gil
Iván J. Núñez-Gil
BIBorja Ibanez
Borja Ibanez
Background The circadian clock influences a number of cardiovascular (patho)physiological processes including the incidence of acute myocardial infarction. A circadian variation in infarct size has recently been shown in rodents, but there is no clinical evidence of this finding. Objective To determine the impact of time-of-day onset of ST segment elevation myocardial infarction (STEMI) on infarct size. Methods A retrospective single-centre analysis of 811 patients with STEMI admitted between 2003 and 2009 was performed. Infarct size was estimated by peak enzyme release. The relationship between peak enzyme concentrations and time-of-day were characterised using multivariate regression splines. Time of STEMI onset was divided into four 6-hour periods in phase with circadian rhythms. Results Model comparisons based on likelihood ratio tests showed a circadian variation in infarct size across time-of-day as evaluated by peak creatine kinase (CK) and troponin-I (TnI) concentrations (p=0.015 and p=0.012, respectively). CK and TnI curves described similar patterns across time, with a global maximum in the 6:00–noon period and a local minimum in the noon–18:00 period. Infarct size was largest in patients with STEMI onset in the dark-to-light transition period (6:00–noon), with an increase in peak CK and TnI concentrations of 18.3% (p=0.031) and 24.6% (p=0.033), respectively, compared with onset of STEMI in the 18:00–midnight period. Patients with anterior wall STEMI also had significantly larger infarcts than those with STEMI in other locations. Conclusions Significant circadian oscillations in infarct size were found in patients according to time-of-day of STEMI onset. The infarct size was found to be significantly larger with STEMI onset in the dark-to-light transition period (6:00–noon). If confirmed, these results may have a significant impact on the interpretation of clinical trials of cardioprotective strategies in STEMI.

1 June 2015 in The American Journal of Medicine
Verified
Journal Article
Closed access
Francesco PellicciaFrancesco Pelliccia
Francesco Pelliccia
GPGuido Parodi
Guido Parodi
CGCesare Greco
Cesare Greco
DADavid Antoniucci
David Antoniucci
RBRoman Brenner
Roman Brenner
JKJuan Carlos Kaski
Juan Carlos Kaski

1 November 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
LNLuis Nombela-Franco
Luis Nombela-Franco
MTMaría del Trigo
María del Trigo
GMGuillermo Morrison-Polo
Guillermo Morrison-Polo
GVGabriela Veiga
Gabriela Veiga
PJPilar Jimenez-Quevedo
Pilar Jimenez-Quevedo
JRJosep Rodés-Cabau
Josep Rodés-Cabau

1 December 2014 in Stem Cell Reports
Verified
Journal Article
Open access
AIAlberto Izarra
Alberto Izarra
IMIsabel Moscoso
Isabel Moscoso
ELElif Levent
Elif Levent
SCSusana Cañón
Susana Cañón
ICInmaculada Cerrada
Inmaculada Cerrada
Antonio BernadAntonio Bernad
Antonio Bernad
MiR-133a and miR-1 are known as muscle-specific microRNAs that are involved in cardiac development and pathophysiology. We have shown that both miR-1 and miR-133a are early and progressively upregulated during in vitro cardiac differentiation of adult cardiac progenitor cells (CPCs), but only miR-133a expression was enhanced under in vitro oxidative stress. miR-1 was demonstrated to favor differentiation of CPCs, whereas miR-133a overexpression protected CPCs against cell death, targeting, among others, the proapoptotic genes Bim and Bmf. miR-133a-CPCs clearly improved cardiac function in a rat myocardial infarction model by reducing fibrosis and hypertrophy and increasing vascularization and cardiomyocyte proliferation. The beneficial effects of miR-133a-CPCs seem to correlate with the upregulated expression of several relevant paracrine factors and the plausible cooperative secretion of miR-133a via exosomal transport. Finally, an in vitro heart muscle model confirmed the antiapoptotic effects of miR-133a-CPCs, favoring the structuration and contractile functionality of the artificial tissue.